COMPASS Pathways plc
CMPSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 3, 2026 | Oppenheimer | Francois Brisebois | $20.00(+133%) | $8.59 | StreetInsider |
| Nov 3, 2026 | BTIG | Madison El-Saadi | $25.00(+184%) | $8.81 | StreetInsider |
| Jul 27, 2026 | Wells Fargo | Benjamin Burnett | $13.00(+15%) | $11.26 | TheFly |
| Jul 20, 2026 | B.Riley Financial | Madison El-Saadi | $17.00(+38%) | $12.35 | StreetInsider |
| Jul 7, 2026 | Stifel Nicolaus | Paul Matteis | $21.00(+62%) | $12.99 | StreetInsider |
| Jul 7, 2026 | Compass Point | $25.00(+91%) | $13.12 | StreetInsider | |
| May 15, 2026 | Maxim Group | Jason McCarthy | $20.00(+92%) | $10.40 | TheFly |
| May 14, 2026 | Morgan Stanley | Judah Frommer | $17.00(+55%) | $10.94 | TheFly |
| May 7, 2026 | UBS | $18.00(+94%) | $9.26 | TheFly | |
| May 3, 2026 | Jefferies | $18.00(+100%) | $9.01 | TheFly | |
| Apr 24, 2026 | UBS | $17.00(+92%) | $8.87 | TheFly | |
| Feb 18, 2026 | RBC Capital | $22.00(+151%) | $8.78 | TheFly | |
| Feb 18, 2026 | Morgan Stanley | Vikram Purohit | $18.00(+136%) | $7.63 | TheFly |
| Feb 18, 2026 | Canaccord Genuity | Sumant Kulkarni | $20.00(+162%) | $7.63 | TheFly |
| Feb 12, 2026 | Compass Point | Francois Brisebois | $15.00(+138%) | $6.31 | TheFly |
| Jan 23, 2026 | RBC Capital | Leonid Timashev | $21.00(+193%) | $7.17 | TheFly |
| Dec 9, 2025 | Oppenheimer | $15.00(+135%) | $6.37 | TheFly | |
| Jul 22, 2024 | RBC Capital | Leonid Timashev | $23.00(+210%) | $7.43 | StreetInsider |
| Jun 5, 2024 | Morgan Stanley | Vikram Purohit | $23.00(+243%) | $6.70 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wells Fargo | maintain | Equal Weight | Nov 4, 2026 |
| BTIG | maintain | Buy | Nov 3, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 7, 2026 |
| B. Riley Securities | maintain | Buy | Aug 6, 2026 |
| Morgan Stanley | maintain | Overweight | Aug 6, 2026 |
| RBC Capital | maintain | Outperform | Aug 6, 2026 |
| Stifel | maintain | Buy | Jul 8, 2026 |
| Evercore ISI Group | upgrade | In Line →Outperform | Jul 8, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 8, 2026 |
| BTIG | maintain | Buy | Jul 7, 2026 |
| Oppenheimer | maintain | Outperform | Jul 7, 2026 |
| Morgan Stanley | maintain | Overweight | Jul 7, 2026 |
| Canaccord Genuity | maintain | Buy | Jun 26, 2026 |
| Maxim Group | maintain | Buy | May 15, 2026 |
| Morgan Stanley | maintain | Overweight | May 14, 2026 |
| RBC Capital | maintain | Outperform | May 14, 2026 |
| BTIG | maintain | Buy | May 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 28, 2026 |
| BTIG | maintain | Buy | Apr 20, 2026 |
| Canaccord Genuity | maintain | Buy | Mar 26, 2026 |
| Morgan Stanley | maintain | Overweight | Mar 25, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 2, 2026 |
| Morgan Stanley | maintain | Overweight | Feb 18, 2026 |
| RBC Capital | maintain | Outperform | Feb 18, 2026 |
| Canaccord Genuity | maintain | Buy | Feb 18, 2026 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $-0.40| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $-0.31 | $-0.39 | — | — |
| Aug 5, 2026 | $-0.36 | $-0.46 | — | — |
| May 13, 2026 | $-0.30 | $-0.45 | — | — |
| Mar 24, 2026 | $-1.00 | $-0.41 | — | — |
| Nov 4, 2025 | $-1.44 | $-0.40 | — | — |
| Jul 31, 2025 | $-0.38 | $-0.37 | — | — |
| May 8, 2025 | $-0.24 | $-0.47 | — | — |
| Feb 27, 2025 | $-0.63 | $-0.62 | — | — |
News
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to nine newly hired non-executive employees. The equity awards were granted on November 2, 2026, and consisted of options to purchase an aggregate of 59,275 shares and restricted share uni…
Compass Pathways (NASDAQ: CMPS) said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within two weeks, as the company prepares for a potential U.S. launch in the first half of 2027. Chief Executive Officer Kabir Nath said the company's submission includes two statistically significant Phase
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Stifel 2026 Healthcare Conference on November 11, 2026 and will participate in a fireside chat at 8:40am ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/4aFtJriVa3BvDmNq…
COMPASS will complete its New Drug Application submission within two weeks. Interventional psychiatrists surveyed show 90% willingness to prescribe COMP360.
COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript
Compass Pathways NASDAQ: CMPS said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within two weeks, as the company prepares for a potential U.S. launch in the first half of 2027.
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the third quarter 2026 financial results and business highlights. "Compass is leading one of the most important advances in mental health care in decades. Millions of people living with TRD are waiting for new treatments that can deliver meaningful and lasting benefit, and we…
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depression and Bipolar Support Alliance (DBSA), today released a new report summarizing findings from a national survey of people living with TRD (n=261) and caregivers (n=73) on the self-reported realities of living with a condition that can profoundly affect daily …
FDA approval could provide a significant catalyst for shares. Wall Street's average price target implies approximately 95% upside.
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place in Colorado Springs, CO, from November 5-8. The Company will feature its Change the Tune in TRD educational campaign for U.S. HCPs focused on TRD, as well as encore presentations…
COMPASS Pathways is currently engaged in a rolling submission and review with the FDA for COMP360 and expects a commercial launch in the first half of 2027. COMPASS is initially targeting the TRD market, which is large and underserved. SPRAVATO has already established the commercial potential of this market, and COMP360 could benefit from reduced dosing frequency. Recent industry M&A also validates the commercial potential of psychedelics, although competitive dynamics and reimbursement are key …
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third quarter ended September 30, 2026, and provide an update on recent developments, on November 3, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 3, 2026. A live webcast of the call…
COMPASS Pathways is rated Buy, with high risk, based on strong trial design and imminent FDA review for COMP360 in treatment-resistant depression. COMP360's Phase 3 trials matched FDA guidance, achieved statistically significant efficacy similar to Spravato, and are positioned for a fast-track FDA decision this quarter. CMPS holds $433.3 million in cash, funding operations into 2028, with valuation implying investors pay 0.57x Spravato's annual sales for COMP360's TRD opportunity.
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the first-ever TRD Awareness Day in the U.S., a day dedicated to recognizing and advocating for individuals, caregivers and communities impacted by TRD. The campaign is being amplified by leading mental health organizations, including National Alliance on Mental Illness (NAM…
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121…
Compass Pathways PLC Sponsored ADR (NASDAQ: CMPS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seventeen brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, fourteen have issued a buy recommendation and
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Bou…
Compass Pathways NASDAQ: CMPS executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potential U.S. launch following FDA approval and federal rescheduling.
Compass Pathways (NASDAQ: CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global Healthcare Conference. Chief Executive Officer Kabir Nath said the company has a rolling
Compass Pathways NASDAQ: CMPS said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its synthetic psilocybin treatment in treatment-resistant depression, or TRD.